Cargando…
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016299/ https://www.ncbi.nlm.nih.gov/pubmed/36918223 http://dx.doi.org/10.1136/jitc-2023-006784 |
| _version_ | 1784907378265686016 |
|---|---|
| author | Immisch, Lena Papafotiou, George Popp, Oliver Mertins, Philipp Blankenstein, Thomas Willimsky, Gerald |
| author_facet | Immisch, Lena Papafotiou, George Popp, Oliver Mertins, Philipp Blankenstein, Thomas Willimsky, Gerald |
| author_sort | Immisch, Lena |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10016299 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100162992023-03-16 Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al Immisch, Lena Papafotiou, George Popp, Oliver Mertins, Philipp Blankenstein, Thomas Willimsky, Gerald J Immunother Cancer Letter BMJ Publishing Group 2023-03-14 /pmc/articles/PMC10016299/ /pubmed/36918223 http://dx.doi.org/10.1136/jitc-2023-006784 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Immisch, Lena Papafotiou, George Popp, Oliver Mertins, Philipp Blankenstein, Thomas Willimsky, Gerald Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al |
| title | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
|
| title_full | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
|
| title_fullStr | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
|
| title_full_unstemmed | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
|
| title_short | Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
|
| title_sort | response to: correspondence on 'h3.3k27m mutation is not a suitable target for immunotherapy in hla-a2+ patients with diffuse midline glioma' by chheda et al |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016299/ https://www.ncbi.nlm.nih.gov/pubmed/36918223 http://dx.doi.org/10.1136/jitc-2023-006784 |
| work_keys_str_mv | AT immischlena responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT papafotiougeorge responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT poppoliver responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT mertinsphilipp responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT blankensteinthomas responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal AT willimskygerald responsetocorrespondenceonh33k27mmutationisnotasuitabletargetforimmunotherapyinhlaa2patientswithdiffusemidlinegliomabychhedaetal |